Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Journal of Applied Pharmaceutical Research
Deka, Himangshu
Unknown Affiliation
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Journal of Applied Pharmaceutical Research

 1 
Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease Basak, Ankita; Ghosh, Soumyadip; Ganguly, Debgopal; Garain, Soukat; Ghosh, Riya; Choudhury, Ananta; Deka, Himangshu; Sarmah, Jahnabi
Journal of Applied Pharmaceutical Research Vol. 11 No. 4 (2023)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18231/j.joapr.2023.11.4.1.9

Abstract

Targeting the drug delivery system is very tough nowadays due to premature drug release at the upper GIT tract and altered pH conditions. Colon-specific drug delivery systems can overcome that problem using different polymer combinations. A nanoparticulate drug delivery system is the prominent dosage form that impacts the bioavailability and requires a low dose to excrete the therapeutic efficacy. All nanoscience and nanotechnology are applications of Nanometrology, the science of measurements at the nanoscale. NPDDSs were primarily developed to combine the colloidal stability of solid particle suspensions in biological fluids and the solubilizing properties of liquids. An ideal drug-delivery system possesses two elements: the ability to target and control the drug release. Colloidal drug carriers offer a number of potential advantages as delivery systems, such as better bioavailability for poorly soluble drugs. Researchers have created various sophisticated and multifunctional nanocarrier systems that can transport pharmaceuticals in a targeted, sustained, and regulated manner to provide therapeutic medications that are safer and more effective, particularly to ulcerative colitis. These innovative technologies are improving the pharmacokinetic profile of pharmaceuticals, increasing their systemic circulation, and decreasing the frequency of pharmacological side effects. The review focuses on the current trend and future perspectives of natural polymer-based-loaded nanoparticle-based drug delivery systems for the management of inflammatory bowel disease.
Comprehensive review of breast cancer risk factors, diagnosis, screening, and treatment methods Hoque, Nurjamal; Choudhury, Ananta; Baishya, Dhiraj; Deka, Himangshu
Journal of Applied Pharmaceutical Research Vol. 12 No. 5 (2024)
Publisher : Creative Pharma Assent

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.69857/joapr.v12i5.606

Abstract

Background: Breast cancer is one of the leading causes of cancer-related deaths among women, accounting for 11.7% of all cancer cases and approximately 685,000 deaths worldwide in 2020. Its multifactorial etiology includes genetic, hormonal, and lifestyle-related risk factors with significant implications for diagnosis and treatment. Understanding these factors and the latest advancements in screening and therapeutic approaches is essential for improving patient outcomes. Methodology: This review synthesizes findings from peer-reviewed articles, clinical trials, and meta-analyses. The focus is on identifying key risk factors for breast cancer, evaluating the effectiveness of current diagnostic methods, and examining the latest treatment strategies, including personalized medicine. Data were collected from PubMed, Scopus, and Google Scholar databases. Results and Discussion: The review highlights major risk factors, including BRCA1/BRCA2 mutations, which contribute to a 45-65% lifetime risk, as well as hormonal influences and lifestyle factors like obesity and alcohol consumption. Targeted therapies, such as HER2 inhibitors (e.g., trastuzumab) and hormone therapies (e.g., tamoxifen), have significantly improved survival rates. Emerging treatments like immunotherapy and PARP inhibitors are also promising for aggressive and metastatic cases. Conclusion: Breast cancer continues to pose a significant health challenge, but advancements in risk assessment, early detection, and personalized treatment offer hope for better outcomes. Continued research and refining diagnostic and therapeutic approaches are essential for reducing breast cancer mortality and enhancing patient quality of life.  
Co-Authors Ananta Choudhury, Ananta Baishya, Dhiraj Basak, Ankita Ganguly, Debgopal Garain, Soukat Ghosh, Riya Ghosh, Soumyadip Hoque, Nurjamal Sarmah, Jahnabi